is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The EUROGIN HPV and Head and Neck Cancer Forum highlights areas of active investigation in the field of HPV and head and neck cancers. It offers a review of the current epidemiologic efforts which focus on the natural history of HPV infection, risk of transmission, screening for early cancer detection, and the potential impact of prophylactic HPV vaccines in the incidence of head and neck cancer, the role of HPV in benign and head and neck disease. The event evaluates how the differing biology of HPV-HNC leads to a re-assessment of clinical staging and clinical prognostic characteristics. Given the viral etiology of these tumors, sessions address to review immune evasion mechanisms utilized by HPV and the understanding of these mechanisms, with the hope of opening the path to novel immunotherapeutic strategies to reactivate the host immune response against the virus and virally-associated cancer cells.
A dedicated debate session will focus on the controversies regarding the impact of HPV infection on oro-pharyngeal cancer, including diagnosis, management and decision making.
Sunday, December 2: 08:30 - 17:00
Monday, December 3: 08:15 - 17:45
Oral presentations 1
Chair: A. Psyrri
Epidemiology of oral HPV infection
Chair: A. Giuliano
Recurrent metastatic HPV related cancer
Chair: P. Bossi
Recurrent Respiratory Papillomatosis
Chair: S. Best
Recurrent Respiratory Papilloma (RRP) is a benign disease affecting the larynx of children and adults caused by infection with low-risk HPV 6 or 11. The need for recurrent surgery and its devastating effects on voice and breathing make treating this disease a great challenge. This session highlights recent developments in the epidemiology of RRP in the era of vaccination, the psychosocial impact of the disease, modern surgical treatment options, and the ongoing search for effective immunologic therapies.
Oral presentations 2
Chair: V. Mehta
HPV and non-oropharynx cancers
Chair: L. Mell
Risk communication and screening for oral HPV mini-presentations and debate
Chair: A. D’souza
-How to screen?
New perspectives on the clinical care of oropharyngeal cancer
Chair: C. Fakhry
Oral presentations 3